Drug Trial Radar · NCT01422187
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Last checked: Nov 20, 2026Latest source record: Apr 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Aug 2011
Primary completion
May 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center trial to further extend the assessment of the safety and efficacy of taliglucerase alfa in adult subjects (≥18 years old) with Gaucher disease who have enrolled in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months or until taliglucerase alfa is commercially available to the subject at the discretion of the Sponsor.
Conditions
- Gaucher Disease
Interventions
Taliglucerase alfaDrug
Taliglucerase infusion every two weeks for 21 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen VolumeTime frame: 60 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.